# A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer

> **NCT04699630** · PHASE2 · COMPLETED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 121 (actual)

## Conditions studied

- Metastatic Breast Cancer
- Locally Advanced Breast Cancer

## Interventions

- **DRUG:** U3-1402

## Key facts

- **NCT ID:** NCT04699630
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-03
- **Primary completion:** 2025-04-09
- **Final completion:** 2025-04-09
- **Target enrollment:** 121 (ACTUAL)
- **Last updated:** 2026-05-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04699630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04699630, "A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-09-01 from https://api.ai-analytics.org/clinical/NCT04699630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*